Medico Intercontinental Ltd

As of November 17, 2025, Medico Intercon. is considered very expensive with a PE ratio of 3266.00, significantly higher than its peers, and has underperformed the market with a year-to-date return of -40.18%.

Medico Intercon has shown significant growth in net sales and profitability, with net sales increasing from 10.30 Cr in Mar'19 to 95.32 Cr in Mar'25, and profit after tax rising from 0.74 Cr to 4.96 Cr. However, the company faced cash flow challenges in the latest fiscal year, reporting a negative cash flow of -7.00 Cr in Mar'25.

The next results date for Medico Intercon is 14 November 2025.

Medico Intercontinental, a microcap in the Trading & Distributors sector, has reported a challenging financial quarter ending June 2025. Despite a 21.53% growth in net sales over six months, the company faces significant hurdles, including a decline in profit after tax and key profitability metrics, alongside a poor year-to-date price performance.

Medico Intercon has shown significant growth in net sales and profitability, with net sales increasing from 10.30 Cr in Mar'19 to 95.32 Cr in Mar'25, and profit after tax rising from 0.74 Cr to 4.96 Cr in the same period, reflecting enhanced operational efficiency and a solid balance sheet.

Medico Intercontinental's latest results are concerning, with a Profit Before Tax of Rs -2.27 crore and a decline in net sales by 11.8% to Rs 21.35 crore, indicating significant financial challenges. The company's profitability and operating margins have also decreased, reflecting a troubling trend.

Medico Intercon. will announce its results on 14 August 2025.

Medico Intercon has shown steady growth in net sales and profitability, with net sales increasing from 10.30 Cr in Mar'19 to 96.02 Cr in Mar'25, and profit after tax rising from 0.74 Cr to 5.06 Cr during the same period. The company's total assets also grew significantly, reflecting its expanding operations.

Medico Intercon has demonstrated strong historical performance, with net sales increasing from 10.30 Cr in March 2019 to 96.02 Cr in March 2025, and a net profit of 5.06 Cr for the same period, reflecting effective cost management and consistent profitability growth.

As of 24th July, Medico Intercontinental Ltd has a market capitalization of 39.00 Cr, with recent Net Sales of 96.01 Cr and a Net Profit of 5.05 Cr. The company's Shareholder's Funds are 45.03 Cr and Total Assets are 56.04 Cr as of March 2024.

Medico Intercontinental Ltd, incorporated in 1984, trades pharmaceutical products and operates as a Micro Cap company with recent net sales of 214 Cr and a net profit of 12 Cr as of March 2025. The company has a market cap of INR 39 Cr and key financial metrics include a P/E of 8.00 and a return on equity of 10.38%.

The top shareholder of Medico Intercon is Shah Samir, holding 44.43% of shares, with no pledged promoter holdings. Individual investors own 39.51%, and the highest public shareholder is Lalita at 1.5%.